Shilpa Medicare gets WHO-Geneva nod for API, Tenofovir Disoproxil Fumarate for HIV, Hepatitis B
Advertisement
Karnataka: Shilpa Medicare Limited has recently announced the receipt of confirmation of WHO - GENEVA approval for API, Tenofovir Disoproxil Fumarate.
The medication is used to treat chronic hepatitis B and to prevent and treat HIV / AIDS, under pre-qualification program.
Read also: Shilpa Medicare secures DRDO nod for manufacturing anti-COVID drug 2DG
Shilpa Medicare Limited started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989.
Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.